Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer

NCT02431559 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Durvalumab
DRUG: Pegylated Liposomal Doxorubicin
DRUG: Motolimod

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]
[object Object]
[object Object]